Study KBP-2020-CPHG Documenting New Cases of Primary Lung Cancer (PLC) Diagnosed in Respiratory Medicine Departments and Lung Cancer Units at General Hospitals From January 1st to December 31st 2020
NCT ID: NCT04402099
Last Updated: 2020-06-05
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
10000 participants
OBSERVATIONAL
2020-01-01
2026-01-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Primary endpoint:
Estimate 1-year- and 5-year-mortality rates in patients with PLC.
Secondary endpoints:
* Describe PLC patient population managed by pulmonologists at French General Hospitals in 2020
* Describe PLC diagnostic and therapeutic management by pulmonologists at French General Hospitals in 2020 and compare them to KBP-2000-CPHG and KBP-2010-CPHG studies
* Estimate prognostic factors
* Compare patient and tumor characteristics to those observed for KBP-2010-CPHG and KBP-2000-CPHG studies
* Compare observed survival rates to those reported for KBP-2000-CPHG and KBP-2010-CPHG studies
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
ESCAP-2020-CPHG: Treatment Strategies Follow-up Implemented During the First Three Years Following Primary Lung Cancer (PLC) Diagnosed in KBP-2020-CPHG Cohort Patients
NCT04419155
The Impact of Polynuclear Neutrophils' Intra-tumoral Rate and the Mutational Status in Pulmonary Adenocarcinomas on Survival
NCT04761640
Epidemiological Study to Describe NSCLC Clinical Management Patterns in Europe. Lung-EPICLIN
NCT00831909
Epidemiologic Multicenter Prospective Study in Advanced NSCLC (Non Small Cell Lung Cancer) Patients With PDL1 (Protein Death Ligand 1) Expression.
NCT02785562
Prospective Multicenter Cohort Study for the Development and Evaluation of Risk Stratification Tools for Lung Cancers and Their Postoperative Recurrences Using Multimodal Clinical, Radiological, Tissue and Longitudinal Biological Phenotyping Among People at Risk of Lung Cancer
NCT07042867
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Primary Lung Cancer histologically (or cytologically or presence of a mutation on liquid biopsy with compatible imaging) proven between January 1st and December 31st, 2020\*
* Follow-up by a lung specialist at a General Hospital
* Oral informed consent \* date of collected sample
Exclusion Criteria
* Secondary lung cancer
* Recurrence of same histological type PLC- left to the investigator discretion according to the clinic and the imagery
* Previous enrolment in the study
* Freedom deprived patient following a legal or administrative decision
* Patient unable to give his(her) consent
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Collège des Pneumologues des Hôpitaux Généraux
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Collège des Pneumologues des Hôpitaux Généraux (CPHG) (General Hospital Pulmonologists College)
Paris, , France
Countries
Review the countries where the study has at least one active or historical site.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
References
Explore related publications, articles, or registry entries linked to this study.
Debieuvre D, Falchero L, Molinier O, Couraud S, Cortot A, Meyer N, Asselain B, Auvray E, Templement-Grangerat D, Bizieux A, Tredaniel J, Schneider S, Auliac JB, Bylicki O, Letierce A, Morel H. Survival of Patients with Lung Adenocarcinoma Diagnosed in 2000, 2010, and 2020. NEJM Evid. 2025 Jul;4(7):EVIDoa2400443. doi: 10.1056/EVIDoa2400443. Epub 2025 Jun 24.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2019-A00943-54
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.